CoChat

Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes

Open access
Jönsson, Cecilia, Castor Batista, Ana P., Kjølhede, Preben, Strålfors, Peter · 2019 · Biochemical Journal

The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index, and 3 are not checked yet.

Abstract

Control of fatty acid storage and release in adipose tissue is fundamental in energy homeostasis and the development of obesity and type 2 diabetes. We here take the whole signalling network into account to identify how insulin and β-adrenergic stimulation in concert controls lipolysis in mature subcutaneous adipocytes obtained from non-diabetic and, in parallel, type 2 diabetic women. We report that, and show how, the anti-lipolytic effect of insulin can be fully explained by protein kinase B (PKB/Akt)-dependent activation of the phosphodiesterase PDE3B. Through the same PKB-dependent pathway β-adrenergic receptor signalling, via cAMP and PI3Kα, is anti-lipolytic and inhibits its own stimulation of lipolysis by 50%. Through this pathway both insulin and β-adrenergic signalling control phosphorylation of FOXO1. The dose–response of lipolysis is bell-shaped, such that insulin is anti-lipolytic at low concentrations, but at higher concentrations of insulin lipolysis was increasingly restored due to inhibition of PDE3B. The control of lipolysis was not altered in adipocytes from diabetic individuals. However, the release of fatty acids was increased by 50% in diabetes due to reduced reesterification of lipolytically liberated fatty acids. In conclusion, our results reveal mechanisms of control by insulin and β-adrenergic stimulation — in human adipocytes — that define a network of checks and balances ensuring robust control to secure uninterrupted supply of fatty acids without reaching concentrations that put cellular integrity at risk. Moreover, our results define how selective insulin resistance leave lipolytic control by insulin unaltered in diabetes, while the fatty acid release is substantially increased.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bcj20190594

Cites

87 of 90 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Control of lipolysis. Adipocytes from non-diabetic subjects were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol (iso) was added and cells incubated for another 10 min. Cells were then separated from medium and fatty acids (n = 26) (a), and glycerol (n = 37) (b) were determined in the medium, and cAMP (n = 20) (c) and the phosphorylation of HSL (n = 19) (d) were determined in the cells. Indicated are P-values for the effect of 0.1 nM insulin compared with no insulin, and to 100 nM insulin, respectively, on isoproterenol-stimulated cells (a–d). Representative immunoblots of one experiment are shown (d).
Figure 1. Control of lipolysis. Adipocytes from non-diabetic subjects were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol (iso) was added and cells incubated for another 10 min. Cells were then separated from medium and fatty acids (n = 26) (a), and glycerol (n = 37) (b) were determined in the medium, and cAMP (n = 20) (c) and the phosphorylation of HSL (n = 19) (d) were determined in the cells. Indicated are P-values for the effect of 0.1 nM insulin compared with no insulin, and to 100 nM insulin, respectively, on isoproterenol-stimulated cells (a–d). Representative immunoblots of one experiment are shown (d).CC BY-NC-ND · PubMed Central
Figure 2. Effect of torin-1 at 1 µM on lipolysis. Adipocytes were pre-incubated without (blue) or with 1 µM torin-1 for 30 min (magenta), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and fatty acids (n = 7) (a) and glycerol (n = 5) (b) were determined in the medium. The phosphorylation of HSL (n = 6) (c, upper panel) and HSL protein (n = 4) (c, lower panel), the phosphorylation of PKB at Ser473 (n = 7) (d) and of PKB at Thr308 (n = 3) (e) were determined in the cells. Indicated are P-values for the effect of torin-1 in isoproterenol-stimulated cells (a–c). Representative immunoblots of one experiment are shown (c–e).
Figure 2. Effect of torin-1 at 1 µM on lipolysis. Adipocytes were pre-incubated without (blue) or with 1 µM torin-1 for 30 min (magenta), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and fatty acids (n = 7) (a) and glycerol (n = 5) (b) were determined in the medium. The phosphorylation of HSL (n = 6) (c, upper panel) and HSL protein (n = 4) (c, lower panel), the phosphorylation of PKB at Ser473 (n = 7) (d) and of PKB at Thr308 (n = 3) (e) were determined in the cells. Indicated are P-values for the effect of torin-1 in isoproterenol-stimulated cells (a–c). Representative immunoblots of one experiment are shown (c–e).CC BY-NC-ND · PubMed Central
Figure 3. Effects of isoproterenol on phosphorylation of PKB. The phosphorylation of PKB at Ser473 (a) and Thr308 (c) in adipocytes in response to 10 nM isoproterenol (iso) and the indicated concentration of insulin (ins) was obtained from the experiments in Figures 2d, 4d, 6c, 7b, 10a, 11a,d and Supplementary Figures S1f and S2b,d (n = 47) (a), and Figures 2e, 4e, 6d, 7c, 10b, and 11b,e (n = 32) (c). The phosphorylation of PKB at Ser473 (n = 13) (b) and Thr308 (n = 4) (d), and the amount of PKB protein (n = 5) (e) were also separately determined in response to 10 nM isoproterenol (iso) for 10 min, when the adipocytes were separated from the medium and the phosphorylation of PKB or the amount of PKB protein determined in the cells. Representative immunoblots are shown from five (b), four (d) and five (e) separate experiments/subjects (underlined).
Figure 3. Effects of isoproterenol on phosphorylation of PKB. The phosphorylation of PKB at Ser473 (a) and Thr308 (c) in adipocytes in response to 10 nM isoproterenol (iso) and the indicated concentration of insulin (ins) was obtained from the experiments in Figures 2d, 4d, 6c, 7b, 10a, 11a,d and Supplementary Figures S1f and S2b,d (n = 47) (a), and Figures 2e, 4e, 6d, 7c, 10b, and 11b,e (n = 32) (c). The phosphorylation of PKB at Ser473 (n = 13) (b) and Thr308 (n = 4) (d), and the amount of PKB protein (n = 5) (e) were also separately determined in response to 10 nM isoproterenol (iso) for 10 min, when the adipocytes were separated from the medium and the phosphorylation of PKB or the amount of PKB protein determined in the cells. Representative immunoblots are shown from five (b), four (d) and five (e) separate experiments/subjects (underlined).CC BY-NC-ND · PubMed Central
Figure 4. Effect of akti1/2 on lipolysis. Adipocytes were pre-incubated without (blue) or with 20 µM akti1/2 for 60 min (brown), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and fatty acids (n = 5) (a) and glycerol (n = 4) (b) were determined in the medium, and cAMP (n = 4) (c), phosphorylation of PKB at Ser473 (n = 4) (d) and Thr308 (n = 4) (e) were determined in the cells. Indicated are P-values for the effect of akti1/2 in isoproterenol-stimulated cells (a–c). Representative immunoblots of one experiment are shown [blots in (d) and (e) are from the same experiment, hence identical β-tubulin blots].
Figure 4. Effect of akti1/2 on lipolysis. Adipocytes were pre-incubated without (blue) or with 20 µM akti1/2 for 60 min (brown), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and fatty acids (n = 5) (a) and glycerol (n = 4) (b) were determined in the medium, and cAMP (n = 4) (c), phosphorylation of PKB at Ser473 (n = 4) (d) and Thr308 (n = 4) (e) were determined in the cells. Indicated are P-values for the effect of akti1/2 in isoproterenol-stimulated cells (a–c). Representative immunoblots of one experiment are shown [blots in (d) and (e) are from the same experiment, hence identical β-tubulin blots].CC BY-NC-ND · PubMed Central
Figure 5. Effect of isoproterenol on phosphorylation of FOXO1. Adipocytes were incubated without or with 10 nM isoproterenol (iso) for 10 min. Cells were then separated from medium and phosphorylation of FOXO1 at Ser256 was determined in the cells (n = 8) (left panel). The amount of FOXO1 protein was determined separately (n = 5) (right panel). Representative immunoblots of five experiments/subjects (underlined) are shown (left panel, from the same experiment as in Figure 3a right panel, hence identical β-tubulin blots).
Figure 5. Effect of isoproterenol on phosphorylation of FOXO1. Adipocytes were incubated without or with 10 nM isoproterenol (iso) for 10 min. Cells were then separated from medium and phosphorylation of FOXO1 at Ser256 was determined in the cells (n = 8) (left panel). The amount of FOXO1 protein was determined separately (n = 5) (right panel). Representative immunoblots of five experiments/subjects (underlined) are shown (left panel, from the same experiment as in Figure 3a right panel, hence identical β-tubulin blots).CC BY-NC-ND · PubMed Central
Figure 6. Effect of wortmannin on lipolysis. Adipocytes were pre-incubated without (blue) or with 0.5 µM wortmannin for 30 min (green), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and glycerol released to the medium was determined (n = 5) (a), and cAMP (n = 9) (b), phosphorylation of PKB at Ser473 (n = 6) (c) and Thr308 (n = 6) (d) were determined in the cells. Indicated are P-values for the effect of wortmannin in isoproterenol-stimulated cells (a and b). Representative immunoblots of one experiment are shown (c and d).
Figure 6. Effect of wortmannin on lipolysis. Adipocytes were pre-incubated without (blue) or with 0.5 µM wortmannin for 30 min (green), when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and glycerol released to the medium was determined (n = 5) (a), and cAMP (n = 9) (b), phosphorylation of PKB at Ser473 (n = 6) (c) and Thr308 (n = 6) (d) were determined in the cells. Indicated are P-values for the effect of wortmannin in isoproterenol-stimulated cells (a and b). Representative immunoblots of one experiment are shown (c and d).CC BY-NC-ND · PubMed Central
Figure 7. Effect of PI3K-inhibitor A66 on lipolysis. Adipocytes were pre-incubated without (blue) or with 10 µM inhibitor A66 of PI3Kα (green/black) for 30 min when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and glycerol released to the medium was determined (n = 5) (a), and the phosphorylation of PKB at Ser473 (n = 6) (b) and Thr308 (n = 4) (c) was determined in the cells. Indicated is P-value for the effect of A66 in isoproterenol-stimulated cells (a). Representative immunoblots of one experiment are shown (b and c).
Figure 7. Effect of PI3K-inhibitor A66 on lipolysis. Adipocytes were pre-incubated without (blue) or with 10 µM inhibitor A66 of PI3Kα (green/black) for 30 min when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and glycerol released to the medium was determined (n = 5) (a), and the phosphorylation of PKB at Ser473 (n = 6) (b) and Thr308 (n = 4) (c) was determined in the cells. Indicated is P-value for the effect of A66 in isoproterenol-stimulated cells (a). Representative immunoblots of one experiment are shown (b and c).CC BY-NC-ND · PubMed Central
Figure 8. Effects of isoproterenol and 8-Br-cAMP on lipolysis and phosphorylation of PKB. Adipocytes were pre-incubated without or with 10 nM isoproterenol (iso) or with 4 mM 8-Br-cAMP, as indicated, (n = 8) for 10 min. Cells were then separated from medium and phosphorylation of PKB at Ser473 and the abundance of PKB protein (a), and the release of glycerol (b) were determined in cells and medium, respectively. Representative immunoblots of one experiment in duplicate (underlined, PKB-Ser473P) or three experiments (underlined, PKB protein) are shown.
Figure 8. Effects of isoproterenol and 8-Br-cAMP on lipolysis and phosphorylation of PKB. Adipocytes were pre-incubated without or with 10 nM isoproterenol (iso) or with 4 mM 8-Br-cAMP, as indicated, (n = 8) for 10 min. Cells were then separated from medium and phosphorylation of PKB at Ser473 and the abundance of PKB protein (a), and the release of glycerol (b) were determined in cells and medium, respectively. Representative immunoblots of one experiment in duplicate (underlined, PKB-Ser473P) or three experiments (underlined, PKB protein) are shown.CC BY-NC-ND · PubMed Central
Figure 9. Effect of insulin on the accumulation of cAMP and lipolysis in the presence of PDE3B inhibitor cilostamide. (a) Adipocytes were pre-incubated without or with 10 µM cilostamide for 30 min, and then without or with 0.1 nM insulin (ins) for 15 min, followed by without or with 10 nM isoproterenol (iso) for a further 10 min, as indicated. After the separation of cells and medium, glycerol was determined in the medium (n = 5). The significance of selected comparisons is indicated. (b and c) Adipocytes were pre-incubated with 10 µM cilostamide for 30 min, and then without (orange) or with (orange with grey border) 0.1 nM insulin for 15 min, when 10 nM isoproterenol (iso) was added and the cells incubated for the indicated time. After separation of cells and medium, cAMP was determined in the cells (n = 5) (b) and glycerol in the medium (n = 5) (c).
Figure 9. Effect of insulin on the accumulation of cAMP and lipolysis in the presence of PDE3B inhibitor cilostamide. (a) Adipocytes were pre-incubated without or with 10 µM cilostamide for 30 min, and then without or with 0.1 nM insulin (ins) for 15 min, followed by without or with 10 nM isoproterenol (iso) for a further 10 min, as indicated. After the separation of cells and medium, glycerol was determined in the medium (n = 5). The significance of selected comparisons is indicated. (b and c) Adipocytes were pre-incubated with 10 µM cilostamide for 30 min, and then without (orange) or with (orange with grey border) 0.1 nM insulin for 15 min, when 10 nM isoproterenol (iso) was added and the cells incubated for the indicated time. After separation of cells and medium, cAMP was determined in the cells (n = 5) (b) and glycerol in the medium (n = 5) (c).CC BY-NC-ND · PubMed Central
Figure 10. Effect of torin-1 at 10 µM on lipolysis. Adipocytes were pre-incubated without (blue) or with 10 µM torin-1 (magenta) for 30 min, when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and the phosphorylation of PKB at Ser473 (n = 4) (a) and Thr308 (n = 5) (b), and cAMP (n = 3) (d) was determined in the cells, and glycerol (n = 8) (c) determined in the medium. Indicated is P-value for the effect of torin-1 in isoproterenol-stimulated cells (c). Representative immunoblots of one experiment are shown (a and b).
Figure 10. Effect of torin-1 at 10 µM on lipolysis. Adipocytes were pre-incubated without (blue) or with 10 µM torin-1 (magenta) for 30 min, when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and the phosphorylation of PKB at Ser473 (n = 4) (a) and Thr308 (n = 5) (b), and cAMP (n = 3) (d) was determined in the cells, and glycerol (n = 8) (c) determined in the medium. Indicated is P-value for the effect of torin-1 in isoproterenol-stimulated cells (c). Representative immunoblots of one experiment are shown (a and b).CC BY-NC-ND · PubMed Central
Figure 11. Effect of A66 + akti1/2 and wortmannin + akti1/2 on lipolysis. Adipocytes were pre-incubated without (blue) (a–f), with 10 µM A66 + 20 µM akti1/2 (a–c) (green and brown), or with 0.5 µM wortmannin + 20 µM akti1/2 (d–f) (green and brown) for 30 min, when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and the phosphorylation of PKB at Ser473 (a and d) or Thr308 (b and e) was determined in the cells, and glycerol released to the medium was determined (c and f) (n = 5). Indicated are P-values for the effect of indicated inhibitors in isoproterenol-stimulated cells (c and f). Representative immunoblots of one experiment are shown [blots in (a) and (b), and in (d) and (e), respectively, are from the same experiment, hence identical β-tubulin blots].
Figure 11. Effect of A66 + akti1/2 and wortmannin + akti1/2 on lipolysis. Adipocytes were pre-incubated without (blue) (a–f), with 10 µM A66 + 20 µM akti1/2 (a–c) (green and brown), or with 0.5 µM wortmannin + 20 µM akti1/2 (d–f) (green and brown) for 30 min, when the indicated concentration of insulin was added and cells incubated for 15 min before incubation with 10 nM isoproterenol (iso) for another 10 min. Cells were then separated from medium and the phosphorylation of PKB at Ser473 (a and d) or Thr308 (b and e) was determined in the cells, and glycerol released to the medium was determined (c and f) (n = 5). Indicated are P-values for the effect of indicated inhibitors in isoproterenol-stimulated cells (c and f). Representative immunoblots of one experiment are shown [blots in (a) and (b), and in (d) and (e), respectively, are from the same experiment, hence identical β-tubulin blots].CC BY-NC-ND · PubMed Central
Figure 12. Complex regulation of cAMP controls lipolysis in response to insulin and βAR signalling. (a) Pathways for control of intracellular cAMP levels and lipolysis by isoproterenol and insulin in human adipocytes. Blue arrows denote insulin signalling and orange arrows denote βAR signalling. 1 and 2 denote the specific indicated signals. (b) A model analysis of the control of PDE3B activity and lipolysis by signals 1 and 2 in (a). The activation of PDE3B by signal 1 (green), and the inhibition of PDE3B by signal 2 (red), were modelled as shown in the left panel. Expression of this model on the activity of PDE3B and lipolysis is shown in the right panels.
Figure 12. Complex regulation of cAMP controls lipolysis in response to insulin and βAR signalling. (a) Pathways for control of intracellular cAMP levels and lipolysis by isoproterenol and insulin in human adipocytes. Blue arrows denote insulin signalling and orange arrows denote βAR signalling. 1 and 2 denote the specific indicated signals. (b) A model analysis of the control of PDE3B activity and lipolysis by signals 1 and 2 in (a). The activation of PDE3B by signal 1 (green), and the inhibition of PDE3B by signal 2 (red), were modelled as shown in the left panel. Expression of this model on the activity of PDE3B and lipolysis is shown in the right panels.CC BY-NC-ND · PubMed Central
Figure 13. At high concentration insulin alone stimulates lipolysis. Adipocytes were incubated for 25 min with the indicated concentration of insulin Cells were then separated from the medium. Indicated are P-values for the effect of the indicated concentration of insulin. Glycerol was determined in the medium (n = 7) (a) and the phosphorylation of HSL (n = 11) (b) was determined in the cells. A representative immunoblot is shown.
Figure 13. At high concentration insulin alone stimulates lipolysis. Adipocytes were incubated for 25 min with the indicated concentration of insulin Cells were then separated from the medium. Indicated are P-values for the effect of the indicated concentration of insulin. Glycerol was determined in the medium (n = 7) (a) and the phosphorylation of HSL (n = 11) (b) was determined in the cells. A representative immunoblot is shown.CC BY-NC-ND · PubMed Central
Figure 14. Control of lipolysis — normally and in T2D. Adipocytes from non-diabetic control subjects (blue) or patients with T2D (red) were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol (iso) was added and cells incubated for another 10 min. The indicated analyte was then determined in the medium (glycerol and fatty acids) or in the cells (cAMP, HSL phosphorylation). Individual subject characteristics and clinical data are presented in Supplementary Table S1. (a) Glycerol: six non-diabetic control subjects [mean age 65 years (range 46–86); mean BMI 24 kg/m2 (range 18–28)] and seven subjects with T2D [mean age 67 years (range 45–77); mean BMI 32 kg/m2 (range 28–40)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.2 mM (range 4.9–7.3); and a mean concentration of insulin of 5.8 mIU/l (range 2.0–11.0). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.2 mM (range 6.3–12); and a mean concentration of insulin of 22 mIU/l (range 5.9–69). Because absolute levels of fatty acid and glycerol released from the adipocytes varied between donors, in order to compare non-diabetic and diabetic cells, data are presented as % of release in the presence of isoproterenol only, in the non-diabetic cells; and in diabetic cells as % of the average release, of all experiments, in the presence of isoproterenol only in the non-diabetic cells. (b) cAMP: seven non-diabetic control subjects [mean age 65 years (range 40–78); mean BMI 26 kg/m2 (range 20–28)] and 10 subjects with T2D [mean age 69 years (range 45–83); mean BMI 33 kg/m2 (range 28–40)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.3 mM (range 5.0–8.7); and a mean concentration of insulin of 8.6 mIU/l (range 1.9–22). The diabetic subjects had a mean fasting plasma concentration of glucose of 8.9 mM (range 5.4–12); and a mean concentration of insulin of 15 mIU/l (range 5.9–39). (c) HSL phosphorylation: nine non-diabetic control subjects [mean age 64 years (range 44–86); mean BMI 25 kg/m2 (range 18–28)] and seven subjects with T2D [same as in (a)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.1 mM (range 4.9–7.3); and a mean concentration of insulin of 6.2 mIU/l (range 2.0–13.0). The diabetic subjects had a mean fasting plasma concentration of glucose and insulin the same as in (a). Representative immunoblots of HSL-P in (c) are shown for one non-diabetic and one diabetic subject. (d) Fatty acids: seven non-diabetic control subjects [mean age 69 years (range 53–86); mean BMI 24 kg/m2 (range 18–28)] and seven subjects with T2D [same as in (a)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.6 mM (range 4.9–7.5); and a mean concentration of insulin of 6.7 mIU/l (range 2.0–13.0). The diabetic subjects had a mean fasting plasma concentration of glucose and insulin the same as in (a). (e) The abundance of HSL was determined by SDS–PAGE and immunoblotting in adipocytes from 10 non-diabetic control subjects (blue) [mean age 46 years (range 34–73); mean BMI 24 kg/m2 (range 20–28)] and 10 subjects with T2D (red) [mean age 55 years (range 45–83); mean BMI 37 kg/m2 (range 31–43)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.0 mM (range 4.8–7.6); and a mean concentration of insulin of 3.9 mIU/l (range 1.6–9.1). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.0 mM (range 5.4–12.3); and a mean concentration of insulin of 31 mIU/l (range 6.0–173). d, diabetic; nd, non-diabetic. (f) Re-esterification was determined. Adipocytes from 18 non-diabetic control subjects (blue) [mean age 62 years (range 43–86); mean BMI 24 kg/m2 (range 20–28)] or seven subjects with T2D (red) [mean age 67 years (range 45–77); mean BMI 32 kg/m2 (range 28–40)] were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol was added and cells incubated for another 10 min. Cells were then separated from medium and fatty acids and glycerol were determined in the medium. The difference between glycerol and fatty acids released (triacylglycerol → 1 glycerol + 3 fatty acids) is defined as reesterification. The reesterification is calculated as % of released fatty acids that were reesterified: 100 × [(3 × glycerol − fatty acids)/3 × glycerol]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.1 mM (range 4.9–8.0); and a mean concentration of insulin of 7.0 mIU/l (range 2.0–16). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.2 mM (range 6.3–12.3); and a mean concentration of insulin of 22 mIU/l (range 5.9–69).
Figure 14. Control of lipolysis — normally and in T2D. Adipocytes from non-diabetic control subjects (blue) or patients with T2D (red) were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol (iso) was added and cells incubated for another 10 min. The indicated analyte was then determined in the medium (glycerol and fatty acids) or in the cells (cAMP, HSL phosphorylation). Individual subject characteristics and clinical data are presented in Supplementary Table S1. (a) Glycerol: six non-diabetic control subjects [mean age 65 years (range 46–86); mean BMI 24 kg/m2 (range 18–28)] and seven subjects with T2D [mean age 67 years (range 45–77); mean BMI 32 kg/m2 (range 28–40)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.2 mM (range 4.9–7.3); and a mean concentration of insulin of 5.8 mIU/l (range 2.0–11.0). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.2 mM (range 6.3–12); and a mean concentration of insulin of 22 mIU/l (range 5.9–69). Because absolute levels of fatty acid and glycerol released from the adipocytes varied between donors, in order to compare non-diabetic and diabetic cells, data are presented as % of release in the presence of isoproterenol only, in the non-diabetic cells; and in diabetic cells as % of the average release, of all experiments, in the presence of isoproterenol only in the non-diabetic cells. (b) cAMP: seven non-diabetic control subjects [mean age 65 years (range 40–78); mean BMI 26 kg/m2 (range 20–28)] and 10 subjects with T2D [mean age 69 years (range 45–83); mean BMI 33 kg/m2 (range 28–40)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.3 mM (range 5.0–8.7); and a mean concentration of insulin of 8.6 mIU/l (range 1.9–22). The diabetic subjects had a mean fasting plasma concentration of glucose of 8.9 mM (range 5.4–12); and a mean concentration of insulin of 15 mIU/l (range 5.9–39). (c) HSL phosphorylation: nine non-diabetic control subjects [mean age 64 years (range 44–86); mean BMI 25 kg/m2 (range 18–28)] and seven subjects with T2D [same as in (a)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.1 mM (range 4.9–7.3); and a mean concentration of insulin of 6.2 mIU/l (range 2.0–13.0). The diabetic subjects had a mean fasting plasma concentration of glucose and insulin the same as in (a). Representative immunoblots of HSL-P in (c) are shown for one non-diabetic and one diabetic subject. (d) Fatty acids: seven non-diabetic control subjects [mean age 69 years (range 53–86); mean BMI 24 kg/m2 (range 18–28)] and seven subjects with T2D [same as in (a)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.6 mM (range 4.9–7.5); and a mean concentration of insulin of 6.7 mIU/l (range 2.0–13.0). The diabetic subjects had a mean fasting plasma concentration of glucose and insulin the same as in (a). (e) The abundance of HSL was determined by SDS–PAGE and immunoblotting in adipocytes from 10 non-diabetic control subjects (blue) [mean age 46 years (range 34–73); mean BMI 24 kg/m2 (range 20–28)] and 10 subjects with T2D (red) [mean age 55 years (range 45–83); mean BMI 37 kg/m2 (range 31–43)]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.0 mM (range 4.8–7.6); and a mean concentration of insulin of 3.9 mIU/l (range 1.6–9.1). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.0 mM (range 5.4–12.3); and a mean concentration of insulin of 31 mIU/l (range 6.0–173). d, diabetic; nd, non-diabetic. (f) Re-esterification was determined. Adipocytes from 18 non-diabetic control subjects (blue) [mean age 62 years (range 43–86); mean BMI 24 kg/m2 (range 20–28)] or seven subjects with T2D (red) [mean age 67 years (range 45–77); mean BMI 32 kg/m2 (range 28–40)] were incubated with the indicated concentration of insulin for 15 min, when 10 nM isoproterenol was added and cells incubated for another 10 min. Cells were then separated from medium and fatty acids and glycerol were determined in the medium. The difference between glycerol and fatty acids released (triacylglycerol → 1 glycerol + 3 fatty acids) is defined as reesterification. The reesterification is calculated as % of released fatty acids that were reesterified: 100 × [(3 × glycerol − fatty acids)/3 × glycerol]. The non-diabetic control subjects had a mean fasting plasma concentration of glucose of 6.1 mM (range 4.9–8.0); and a mean concentration of insulin of 7.0 mIU/l (range 2.0–16). The diabetic subjects had a mean fasting plasma concentration of glucose of 9.2 mM (range 6.3–12.3); and a mean concentration of insulin of 22 mIU/l (range 5.9–69).CC BY-NC-ND · PubMed Central
Figure 15. Lipolytic control by βAR integrated in the insulin signalling network of human adipocytes. The integrated comprehensive signalling network of insulin and β-adrenergic acute signalling in human adipocytes that we have defined in isolated primary human adipocytes, normally and in T2D [23,25–28,31,62,80,81] and herein. Blue arrows denote insulin signalling and orange arrows denote signalling by the βAR. Hatched blue and orange arrows denote joint signalling by insulin and βAR. The thicker arrows represent signalling investigated herein. The red arrows indicate that the impaired signalling in T2D is due to attenuated mTORC1 signalling and attenuated fatty acid esterification. Long term regulation of protein levels via transcriptional or translational control is not included in the scheme, and it can be noted that in type 2 diabetes maximal stimulation of glucose uptake is reduced in type 2 diabetes, because of down-regulated levels of GLUT4 [82] that apparently is due to reduced levels of the transcription factor FOXO1 in T2D [24,27]. FOXO1, in turn, appears to be reduced by the attenuated mTORC1 signalling in T2D [27].
Figure 15. Lipolytic control by βAR integrated in the insulin signalling network of human adipocytes. The integrated comprehensive signalling network of insulin and β-adrenergic acute signalling in human adipocytes that we have defined in isolated primary human adipocytes, normally and in T2D [23,25–28,31,62,80,81] and herein. Blue arrows denote insulin signalling and orange arrows denote signalling by the βAR. Hatched blue and orange arrows denote joint signalling by insulin and βAR. The thicker arrows represent signalling investigated herein. The red arrows indicate that the impaired signalling in T2D is due to attenuated mTORC1 signalling and attenuated fatty acid esterification. Long term regulation of protein levels via transcriptional or translational control is not included in the scheme, and it can be noted that in type 2 diabetes maximal stimulation of glucose uptake is reduced in type 2 diabetes, because of down-regulated levels of GLUT4 [82] that apparently is due to reduced levels of the transcription factor FOXO1 in T2D [24,27]. FOXO1, in turn, appears to be reduced by the attenuated mTORC1 signalling in T2D [27].CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 90 references

Cited by

See all 34

Metadata

Authors
Jönsson, C., Castor Batista, A. P., Kjølhede, P., & Strålfors, P.
Affiliations
  • Linköping University (SE)
  • Department of Clinical and Experimental Medicine, Linköping University, SE58185 Linköping, Sweden
Corresponding author
Strålfors, Peter
Venue
Biochemical Journal
Published
2019-10-11
Volume
476
Issue
19
Pages
2883-2908
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
OpenAlex
W2972545941
Cited by
34
References
87
Citations by year
2026: 3 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 5 · 2021: 9 · 2020: 8
FWCI
2.30
Type
journal article
Language
en
Open access
Locations
  • Biochemical Journal (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DiVA (Linkoping University) (submittedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
insulin signaling, beta-adrenergic receptors, lipolysis, type 2 diabetes, human adipocytes, PDE3B, Akt/protein kinase B, cyclic AMP, PI3Kα, FOXO1 phosphorylation, fatty acid release, fatty acid re-esterification, insulin resistance, energy homeostasis
MeSH terms
Adipose Tissue, Adolescent, Adult, Aged, Aged, 80 and over, Cells, Cultured, Diabetes Mellitus, Type 2, Female, Humans, Insulin, Lipolysis, Middle Aged, Obesity, Receptors, Adrenergic, beta, Adipocytes, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes. https://app.cochat.ai/papers/10.1042/bcj20190594
The paper
Jönsson, C., Castor Batista, A. P., Kjølhede, P., & Strålfors, P. (2019). Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes. Biochemical Journal. https://doi.org/10.1042/bcj20190594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.